SCHEMBL2326320

SCHEMBL2326320

COc1ccc(S(=O)(=O)Nc2ccc3c(c2)nc(-c2ccccc2)n3-c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
PTPN2 P17706 4/20 0.58
PTPN1 P18031 4/20 0.58
PTPN5 P54829 4/20 0.58
ALDH1A1 P00352 3/20 0.58
HTT P42858 2/20 0.58
LMNA P02545 2/20 0.58
HPGD P15428 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
GAA P10253 1/20 0.55
ALOX12 P18054 1/20 0.55
NPY5R Q15761 1/20 0.52
PLAU P00749 1/20 0.51
TP53 P04637 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PKM P14618 3/20 0.50
POLB P06746 1/20 0.50
CYP19A1 P11511 1/20 0.50
PGR P06401 1/20 0.50
TRIM24 O15164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2330704 0.93 MAPT (0.56) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL4588933 0.91 MAPT (0.50) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL4589934 0.89 PTPN2 (0.57) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2330377 0.89 HPGD (0.52) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2331010 0.86 PTPN2 (0.56) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2326303 0.86 PTPN2 (0.56) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2326768 0.86 SMN1; SMN2 (0.49) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2330144 0.84 PTPN2 (0.58) PTPN2PTPN1PTPN5ALDH1A1LMNA
SCHEMBL2323585 0.83 PTPN2 (0.59) MAPTPTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2328365 0.80 PTPN2 (0.58) MAPTPTPN2PTPN1PTPN5LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246808-B1 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION BAYER SCHERING PHARMA AG (DE) 2011-08-17 EP disclosed
US-7329679-B2 1,2 Diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2008-02-12 US disclosed
US-7115645-B2 1,2 diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-10-03 US disclosed
US-20060094770-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-05-04 US disclosed
EP-1246808-A1 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION SCHERING AKTIENGESELLSCHAFT (DE) 2002-10-09 EP disclosed
US-20020006948-A1 1,2 diarylbenzimdazoles and their pharmaceutical use SCHERING AG 2002-01-17 US disclosed
WO-2001051473-A1 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION SCHERING AKTIENGESELLSCHAFT (DE) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006948-A1 1,2 diarylbenzimdazoles and their pharmaceutical use CYP2E1, CYP1B1, CYP1A1 MAPT 1799/4885PTPN2 2206/4885PTPN1 1872/4885
US-20060094770-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use ATP6V1B2, IL1B, GMFG MAPT 829/4885PTPN2 1930/4885PTPN1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.